Bottom line
Is BIS a good fund? The bottom line
BIS is an actively managed leveraged & inverse ETF from ProShares.
It charges 0.95% — about $95 a year on every $10,000 invested, cheaper than 82% of leveraged & inverse funds we track.
It returned −46.1% over one year, −15.1% a year over five years, −21.2% a year over ten (as of Dec 31, 2025, per its prospectus).
With $2.4 million in net assets and 9 holdings, its largest position is Repurchase Agreement (40.6%) and the top 10 make up 54% of the portfolio.
What stands out
- Low cost: cheaper than 82% of leveraged & inverse peers
What to watch
- Concentrated: top 10 holdings are 54% of assets
- Small fund ($2.4 million) — small funds are likelier to close
Updated Nov 19, 2026
What BIS invests in
ProShares UltraShort Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology Index (the Index).
The Fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The Index is designed to measure the performance of a set of Nasdaq-listed biotechnology and pharmaceutical companies. The Index includes companies listed on the Nasdaq Global Select Market or the Nasdaq Global Market (which include both U.S. and non-U.S. companies) that are included in the biotechnology or pharmaceuticals subsectors, according to the Industry Classification Benchmark. The biotechnology and pharmaceutical subsectors include companies engaged in research into and development of biological substances for the purposes of drug discovery and diagnostic development and manufacturers of prescription or over-the-counter drugs. Companies are selected based on market capitalization and liquidity. Selected companies are then…
From the fund's prospectus (filed Sep 25, 2026).
BIS performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| BIS | −46.1% | −15.1% | −21.2% |
| Leveraged & Inverse median | −7.7% | −11.8% | −13.5% |
Source: Fund prospectus, as of Dec 31, 2025
What BIS costs
On a $10,000 investment, BIS's 0.95% expense ratio costs about $95 a year. The prospectus estimates $3,943 in total costs over 10 years (assuming 5% annual returns). The median leveraged & inverse fund charges 1.31%.
BIS top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Repurchase Agreement | 40.64% |
| 2 | Repurchase Agreement | 25.57% |
| 3 | Repurchase Agreement | 19.18% |
| 4 | Repurchase Agreement | 14.06% |
| 5 | N/a | -3.64% |
| 6 | N/a | -3.75% |
| 7 | N/a | -10.52% |
| 8 | N/a | -11.12% |
| 9 | N/a | -16.39% |
Source: SEC Form N-PORT, period ended May 31, 2026
The top 10 make up 54% of the fund. See all top 25 holdings and asset mix →